Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie’s Way Plus
https://finance.yahoo.com/news/brainsway-broadens-access-deep-tms-113000032.html
Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems
BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that its longstanding partner, Katie’s Way Plus, which provides comprehensive mental health services tailored to the unique needs of active duty military members, veterans, and their families, has ordered an additional 10 Deep Transcranial Magnetic Stimulation (Deep TMS™) systems, which will more than double its existing offering.
“This is yet another demonstration of our strategic focus on larger enterprise customers across the U.S.,” said Eric Hirt, VP U.S. Sales of BrainsWay. “The strategic collaboration between BrainsWay and Katie's Way Plus is poised to make a substantial impact on addressing the critical and unique mental health issues faced by military personnel by providing world-class care to those who have served their country and are in need of advanced solutions to address their specialized conditions.”
“We are thrilled to support Katie's Way Plus in its vital mission to provide focused care to U.S. service members, veterans, and their families,” said Hadar Levy, Chief Executive Officer of BrainsWay. “BrainsWay's advanced Deep TMS technology has demonstrated remarkable clinical efficacy in treating depression, and we are confident that this expansion will bring hope and healing to many U.S. service members.”
“Katie's Way was founded in memory of my daughter, Katie, who tragically lost her battle with depression,” said Jeff Mathis, Founder of Katie’s Way. “Our goal is to ensure that no other family needs to endure such pain. These additional BrainsWay systems will allow us to extend our reach, offer hope, and ultimately save lives.”
Depression is a contributing factor to suicide, which is a particularly pressing concern within the military community. September is Suicide Prevention Month, which helps raise awareness to the fact that 22 U.S. military veterans take their lives each dayi.
BrainsWay Deep TMS is delivered via a unique treatment coil housed in a cushioned, patient and provider-friendly helmet. The patient is awake, alert, and engaged during the treatment session, and each session only takes less than 30 minutes from start to finish. For some patients, a shorter three-minute intermittent theta burst (iTBS) protocol is also an option. Most candidates for Deep TMS depression treatment have already failed multiple courses of medication and talk therapy, and in a recently published post-marketing analysis of close to 1,400 patients, those patients who had received 30 or more treatments of Deep TMS demonstrated an 82% response rate and a 65% remission rateii.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
About Katie’s Way
Katie's Way TMS is a trailblazing mental health care provider with a heartfelt commitment to improving the lives of active duty military service members, veterans, and their families. Founded by Jeff Mathis, our mission is deeply rooted in a profound personal loss. Jeff's daughter, Katie, tragically lost her battle with depression, inspiring him to establish Katie's Way with a resolute determination to prevent others from experiencing a similar tragedy. At Katie's Way TMS, our focus is clear: to provide specialized care, hope, and healing to those who have selflessly served our nation. We understand the unique challenges that military members, veterans, and their families face when it comes to mental health, and we are dedicated to addressing these challenges head-on. With unwavering commitment, Katie's Way TMS strives to make a meaningful impact by providing accessible, evidence-based care to individuals who have sacrificed so much for our country. Our journey is driven by the memory of Katie and the hope that no other family will have to endure the pain of losing a loved one to depression. Katie’s Way currently operates 5 treatment facilities in the United States, and will expand to 12-15 clinics by early 2024. To learn more, please visit www.katieswayplus.com.
4.7200+0.3900 (+9.0069%)
As of 11:17AM EDT. Market open.
Momentum continues:
Volume 378,206
Avg. Volume 51,124
BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.
https://finance.yahoo.com/news/brainsway-forges-strategic-partnership-treatment-113000648.html
10 Deep TMS™ Systems to be Installed in 2023 Alone
BURLINGTON, Mass. and JERUSALEM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments, today announced the formation of a strategic partnership with a prominent mental health clinical treatment provider with an increasingly expanding footprint in the Northeast region of the United States. As a result of this partnership and a series of successive orders, a total of 10 Deep Transcranial Magnetic Stimulation (Deep TMS™) systems will be installed by this provider in 2023 alone, with the potential for additional systems thereafter.
"We are thrilled to strengthen our relationship with this esteemed and rapidly growing mental health services provider,” said Hadar Levy, Chief Executive Officer of BrainsWay. “Their order of 10 systems this year alone, with interest in additional systems in the future, is a testament to this customer’s confidence in BrainsWay’s status as the premier TMS technology platform in the industry.”
The announcement is the latest demonstration of the Company’s increasing traction with a variety of new institutional and enterprise customers in the U.S and internationally.
“We remain steadfast in our mission to redefine mental health treatment by leveraging our advanced and unique Deep TMS technology to address the alarming global increase in the prevalence of mental health conditions and the corresponding rise in demand for innovative and effective treatment modalities,” concluded Mr. Levy.
$BWAY - 🚀Up 10% Pre-Market/Current Price $2.58
👉Reports Q2 '23 Financial Results and Operational Highlights
👉For the 3 months ended June 30 '23, revenues were $7.8m, an 18% increase as compared to the Q1 '23. Gross margin for the Q2 '23 was 73%
BrainsWay Announces Publication of Three New Deep TMS Research Publications
https://finance.yahoo.com/news/brainsway-announces-publication-three-deep-120000767.html
New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research
BURLINGTON, Mass. and JERUSALEM, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced three recent publications highlighting its Deep Transcranial Magnetic Stimulation (Deep TMS™) in leading peer-reviewed medical journals.
Two of the publications enhance understanding of the safety profile of TMS. The first, published in Brain Stimulation, provides a concise overview of the adverse event profile of the H1, H4, and H7 Coils as studied in five (5) large, multicenter, randomized controlled trials (RCTs). It is the most transparent review on the safety record of a TMS device, and the only one of its kind published by a TMS manufacturer. The second, published in the Journal of Clinical Psychiatry and on Psychiatrist.com, provides practical recommendations on performing TMS on patients having metallic implants, a common contraindication for all forms of TMS.
The third, published in Brain Sciences, is a comprehensive review on the use of TMS to address smoking addiction, an existing indication supported by clinically proven efficacy, and potential indications including alcohol use disorder (AUD) and other substance use disorders (SUDs). BrainsWay Deep TMS™ for smoking addiction represents the only FDA-cleared TMS solution for any addiction. The publication highlights preliminary research of Deep TMS in various other addictions, and underscores the need for further randomized controlled clinical trials in these difficult-to-treat conditions.
“One of BrainsWay’s three pillars is ‘superior evidence,’ and we are committed to advancing the field of neuroscience through a greater understanding of this life-changing technology for mental health patients, their caregivers, and providers,” said Colleen Hanlon, Ph.D., BrainsWay’s Vice President of Medical Affairs and Director of Innovation. “The body of evidence supporting Deep TMS is unparalleled in depth and breadth, and we are excited to continue conducting research and analyzing existing datasets to provide our customer partners with informed science to best treat their patients.”
BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights
https://finance.yahoo.com/news/brainsway-reports-first-quarter-2023-113000884.html
BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter 2023 financial results and provided an operational update.
Recent Financial and Operational Highlights
For the three months ended March 31, 2023, revenues were $6.6 million, a 10% increase as compared to the fourth quarter of 2022.
The Company shipped a net total of 48 Deep TMS™ new systems during the first quarter of 2023, bringing BrainsWay’s total Deep TMS installed base to 932 total systems as of March 31, 2023, an 18% increase from the installed base at the same point in the prior year.
As of March 31, 2023, the Company had shipped 453 obsessive-compulsive disorder (OCD) coils as add-on helmets to certain of BrainsWay’s new and existing systems, representing OCD treatment capability on nearly 50% of its total installed base.
Cash, cash equivalents, and short-term deposits as of March 31, 2023, amounted to $44.3 million, compared to $47.9 million as of December 31, 2022.
Recently published compelling data in Psychiatry Research demonstrating high response and remission rates for depression and anxious depression patients undergoing Deep TMS™ treatment.
Data from the expansive post-marketing study demonstrated that patients who had received 30 or more treatments achieved an 82% response rate and a 65% remission rate in depression symptoms. Outcomes data from 1,351 patients evaluated in the study showed that average sustained response was achieved at 16 sessions, or 21 days after beginning treatment with Deep TMS.
Continued to achieve reimbursement progress, increasing access for patients to the Deep TMS system.
BlueCross BlueShield of Mississippi issued a healthcare policy update that allows TMS trained healthcare professionals to order and provide TMS treatment to their patients with major depressive disorder (MDD).
United HealthCare has updated their Medicare Advantage policy in states covered by National Government Services Medicare to allow non-physician practitioners, like nurse practitioners, to order and administer TMS Therapy to their patients with MDD in states where they have scope of practice to do so.
“We remain focused on implementing key initiatives aimed at growing the Company’s top-line while simultaneously advancing toward profitability,” said Hadar Levy, BrainsWay’s Chief Executive Officer. “Importantly, we are gaining strong interest from our international business which increased significantly during the first quarter and helped facilitate our shipment of a net total of 48 systems during the quarter.”
“We also executed a number of cost optimization measures late in the first quarter that we expect to begin seeing the benefits of in the second quarter, and more meaningfully in the second half of this year,” continued Mr. Levy. “We continue to target breakeven operating income in the fourth quarter of 2023, while demonstrating full-year revenue growth over 2022.”
First Quarter 2023 Financial Results
Total revenues for the first quarter of 2023 were $6.6 million, compared to $8.0 million in the first quarter of 2022, a decrease of 17%.
Gross margin for the first quarter of 2023 was 73%, compared to 77% for the first quarter 2022.
Operating expenses for the first quarter of 2023 totaled $8.5 million, compared to $7.6 million for the first quarter of 2022.
Operating loss for the first quarter of 2023 was $3.7 million, compared to a loss of $1.5 million for the same period in 2022.
Net loss for the first quarter of 2023 was $2.4 million, compared to a loss of $2.0 million for the same period in 2022.
Conference Call and Webcast
BrainsWay’s management will host a conference call on Wednesday, May 17, 2023, at 8:30 a.m. Eastern Time to discuss these results and answer questions.
Wednesday, May 17, 2023, at 8:30 AM Eastern Time:
United States:
1-877-407-3982
International:
1-201-493-6780
Israel:
1-809-406-247
Conference ID:
13738617
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1613817&tp_key=17843474e5
To listen to a live webcast, please visit the Investors section of the BrainsWay website at www.BrainsWay.com. Please access the Company’s website at least 10 minutes ahead of the conference call to register. The webcast replay will be available on the website for two weeks following the completion of the call.
Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder
https://finance.yahoo.com/news/publication-analyzes-clinical-efficacy-deep-130000866.html
Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain Stimulation
BURLINGTON, Mass. and JERUSALEM, Jan. 31, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of a comparative study of BrainsWay’s Deep Transcranial Stimulation (Deep TMS™) H1 Coil, which targets the lateral prefrontal cortex, and the Company’s H7 Coil, which targets the medial prefrontal cortex. Published in The Journal of Clinical Investigation (JCI) Insight, the study, which enrolled 169 treatment-resistant depression patients, validates the efficacy of both BrainsWay coils for depression, and also identifies preliminary predictors that could help optimize treatment based on individual patients’ attributes.
The primary endpoint of the study – non-inferiority of the H7 Coil in reducing depressive scores when compared to the H1 Coil – was successfully demonstrated among the overall patient population. This study served as the basis for BrainsWay’s August 2022 H7 Coil FDA clearance for depression. This publication of the study also includes a new retrospective analysis of the clinician rating scales and EEG data, revealing intriguing differences between the patient treatment of the two coils. Categorizing patients according to “clusters” of clinical depressive and anxiety baseline symptoms derived from a subset of the Hamilton Depression Rating Scale (HDRS-21) resulted in two subject groups: One with higher severity of the cluster, which on average responded better to the H1 Coil, and another with lower severity of the cluster, which on average responded better to the H7 Coil. This retrospective analysis was referred to in the publication as the “Clinical Differential Predictor” for TMS H-Coils.
Another interesting finding involved retrospective EEG analysis, which showed that brain activity measured during the first treatment session correlated with the clinical outcomes ultimately achieved after the full course of treatment. This finding suggests that specific brain patterns observed in an individual’s response to either coil during the early stages of treatment might be predictive of the longer-term outcome of treatment with that coil.
“This study is a significant milestone for depression and anxious depression patients and reinforces our commitment to bring mental health within reach for all,” said Christopher von Jako, Ph.D., President and CEO of BrainsWay.
“This study is an important scientific step forward toward personalized psychiatry,” said Prof. Abraham Zangen, Head of the Brain Stimulation and Behavior Lab and the Chair of the PsychoBiology Brain Program at Ben-Gurion University and a scientific consultant for and member of the board of directors of BrainsWay. “Previously published case series had indicated that the H7 Coil was potentially effective in treating depression in patients that did not achieve response or remission after undergoing treatment with TMS coils which target the lateral prefrontal cortex. While the similar reduction in depression scores notably validated the non-inferiority between the H1 and H7 Coils, we were truly inspired by the subsequent retrospective analyses of the clinician rating scales and EEG data. Once we apply the categorization technique employed in this study, the potential exists to increase depression response rates even further. For example, patients categorized as having high cluster severity demonstrated response rates of 95%. We look forward to further validating these preliminary predictors in subsequent research as we continue our quest to optimize patient outcomes.”
The paper, “Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS,” was published in The Journal of Clinical Investigation (JCI) Insight. For more information, please visit: https://insight.jci.org/articles/view/165271
About Major Depressive Disorder and Anxious Depression
Major depressive disorder (MDD) is a common and debilitating form of depression characterized by physiological, emotional, and cognitive symptoms. According to the World Health Organization (WHO), depression affects approximately 264 million people worldwide, and the U.S. National Institute of Mental Health (NIMH) estimates that 21 million adults in the United States suffer from an MDD episode within a given year. Common symptoms of MDD include loss of interest, depressed mood, reduced energy, disturbed sleep, and changes in appetite. 60-90% of depression patients also exhibit comorbid moderate to severe anxiety, a condition commonly referred to as anxious depression. These anxiety symptoms include nervousness, feelings of panic, increased heart rate, rapid breathing, sweating, insomnia, trembling, and difficulty focusing or thinking clearly. The economic burden in the United States for major depressive disorder totaled $326 billion prior to the recent COVID pandemic.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.
Contacts:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@BrainsWay.com
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
Media Contact:
Meghan Laska
(610) 212-0125
Meghan.Laska@BrainsWay.com
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
https://finance.yahoo.com/news/brainsway-announces-extended-private-insurance-130000484.html
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that a major private insurance company in Washington state will extend positive coverage applicable to Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of obsessive-compulsive disorder (OCD) as of February 3, 2023. This policy extension provides coverage of Deep TMS for OCD to approximately 2.2 million members.
The policy change also reduces major depressive disorder (MDD) TMS coverage criteria from four failed medication trials to only three. OCD coverage criteria is also three failed medication trials.
“Over the past two years, BrainsWay has seen significant coverage expansion of Deep TMS, including reduced patient selection criteria and earlier access to treatment for both MDD and OCD patients,” said Scott Blackman, Director of Market Access of BrainsWay. “This has been especially evident in the Medicare population where all Medicare administrative contractors now cover depression with only one or two failed medication trials.”
BrainsWay continues to focus on informing and providing payers with its growing body of published clinical and real-world evidence to facilitate up-to-date evidence-based coverage determinations. In 2021, only 52.6 million U.S. lives were covered for OCD treatment with TMS. Last year, insurers such as Cigna, Highmark BCBS, and Palmetto GBA Medicare extended coverage, increasing the total covered lives to 90.5 million.
BrainsWay’s patented H-Coil technology was first FDA-cleared for treating MDD in 2013 and OCD in 2018, and is designed to penetrate deeper and broader structures of the brain than traditional TMS coils.
BrainsWay Resolves Neuronetics Litigation
https://finance.yahoo.com/news/brainsway-resolves-neuronetics-litigation-130000356.html
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that it has settled litigation filed by Neuronetics, Inc. (“Neuronetics”) in the District of Delaware.
BrainsWay had filed a motion to dismiss the case, and, while that motion was pending, agreed to settle the case on mutually agreeable terms and without any admission of liability or wrongdoing, including the release of certain potential counterclaims, to avoid the time, expense and uncertainty of litigation. “We are pleased to have resolved this litigation so that we can focus our full attention on our technology and bringing our Deep TMS™ therapy to patients,” said Christopher von Jako, P.h.D., President and CEO of BrainsWay.
Except as set forth in this press release, and a corresponding announcement from Neuronetics, the parties have agreed to keep the terms of the settlement agreement confidential.
BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom
https://finance.yahoo.com/news/brainsway-reports-open-market-stock-141500758.html
BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported a recent open market purchase of BrainsWay American Depositary Receipts (ADRs) by Yossi Ben Shalom, an independent Director on the Company’s Board.
Mr. Ben Shalom purchased 147,500 ADRs (representing 295,000 ordinary shares) on the open market for a total amount of $277,300, at an average price of $1.88 per ADR.
“This investment reflects my strong belief in the value of BrainsWay, its technology, and its strategic vision,” stated Mr. Ben Shalom. “The Company’s impressive dossier of clinical evidence has shown that its unique, patented, and FDA-cleared Deep TMS™ platform is highly impactful in treating multiple indications. Based on its effective business model and industry leading R&D capabilities, as well as favorable market trends, I believe BrainsWay represents a highly compelling long-term strategic investment.”
The ADR purchase was made on the Nasdaq exchange, and follows recent open market stock purchases by additional BrainsWay board members, including its Chairman, Dr. David Zacut, and Avner Hagai. The Company’s ordinary shares are listed and traded on the Tel Aviv Stock Exchange.
In addition to having served on BrainsWay’s board since 2018, Mr. Ben Shalom is a board member at several other companies, and is a co-founder of D.B.S.I, a private investment company specializing in mature companies that are positioned globally for high growth.